Laurus Labs Reports Strong Q1 FY26 Performance, Driven by CDMO & Generics Growth, Advances Strategic Investments
The announcement details strong quarterly financial results indicating operational efficiency and growth across key segments. Furthermore, it outlines substantial strategic investments, including a new fermentation site, an R&D facility in Hyderabad, a significant joint venture with KRKA, and expansion into Cell and Gene Therapy, which are expected to drive future growth and diversify revenue streams.
The company reported significant year-on-year growth in Q1 FY26 revenues (31%), EBITDA (127%), and Net Profit (1154%), with improved gross and EBITDA margins. This strong financial performance is supported by robust CDMO momentum, growth in Generics, and strategic investments in expanding manufacturing capabilities and advanced therapies like Cell and Gene Therapy.
* Laurus Labs Limited reported strong financial performance for Q1 FY26, with revenues increasing by 31% year-on-year to ₹ 1,570 crore. * EBITDA surged by 127% year-on-year to ₹ 389 crore, with EBITDA margins improving by 10.5 percentage points to 24.8%. * Net Profit for Q1 FY26 rose by 1,154% year-on-year to ₹ 163 crore. * The strong performance was primarily driven by robust Contract Development & Manufacturing Organization (CDMO) momentum and growth in Generics, partly offset by lower API business. * The company is actively strengthening its CDMO capabilities, with over 110 active projects and continued investment in commercial capacity at Vizag and a new 200,000 sq. ft. R&D site in Hyderabad. * In the BIO segment, Laurus Labs is expanding its enzymatic/bio-catalysis applications and has broken ground for a large-scale Fermentation manufacturing site in Vizag, expected to be operational by end of 2026. * The Generics business is focused on capacity optimization, cost efficiency, and expanding CMO collaborations, with FDF new manufacturing lines expansion on track, expected to be commissioned by December 2025. * The joint venture with KRKA Pharma Private Limited (51:49 share) is progressing, with a groundbreaking ceremony for a finished formulation manufacturing facility in Hyderabad. Laurus Labs invested ₹ 105 crore in FY25 and committed to invest over ₹ 500 crore in the initial phase, with project completion expected by mid-2027. * In Cell and Gene Therapy, the NexCAR19 therapy continues to see demand (>350 infusions as of June 2025), and a second GMP facility in Navi Mumbai is commencing operations in September 2025 to add 2,500 treatment capacity. * A new dedicated Gene/Anti-body Drug Conjugates R&D and manufacturing facility is being developed in Genome Valley, Hyderabad, with an expected investment of over US$ 25 million (approximately ₹ 208.5 crore), to start operations by end of 2026. * The company's total CAPEX for FY22-26 is approximately ₹ 3,400 crore, with over 85% allocated to growth CAPEX across the API/CDMO portfolio. * Management commented that Q1 FY26 saw strong performance with attractive market opportunities favoring robust CDMO momentum, expanding collaboration in complex API, and growth in Generics.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.